Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matching, dyslipidemia was signif. higher w/ TOFA (HR 1.25), BUT no differences in MACE (HR 0.995) or all-cause mortality (HR, 1.4; NS) https://t.co/ZJ7uHWTycS https://t.co/A6tSm4RipS
Links:
Frontiers | Risk of Dyslipidemia and Major Adverse Cardiac Events with Tofaciti…
https://buff.ly/4bpQ8rN
May-21-2024
